OHDSI MEETINGS THIS WEEK
OHDSI STATEMENT ON COVID-19: OHDSI is committed to doing what it can to support and inform the COVID-19 pandemic response, and will prioritize activities aligned to this effort. As we adjust to the current global situation, the OHDSI community will continue to have our regular Tuesday community calls, as well as our various working group calls. Understandably, some calls could be postponed or cancelled due to issues surrounding COVID-19, so we ask that you continuously check the OHDSI forums, weekly digest and social channels for updated information. OHDSI is a virtual community, so we are equipped to continue collaboration during this challenging time.
OMOP CDM Oncology WG - Genomic Subgroup Meeting - Tuesday at 9am EThttps://us04web.zoom.us/j/412862164?pwd=NmpEWTdTQlB4N3VxT0tQRXdDWlg0dz09 https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg
OMOP CDM Oncology WG - Leadership Subgroup Meeting - Tuesday at 10am EThttps://us04web.zoom.us/j/988206409?pwd=QzdEZndhelFKSzdKblhubmZvYzkwZz09 https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg
OHDSI Community Call - Tuesday at 12pm EThttps://columbiacuimc.zoom.us/j/945377669 https://www.ohdsi.org/web/wiki/doku.php?id=projects:ohdsi_community
Oncology WG - Development Subgroup Meeting - Wednesday at 10am EThttps://www.ohdsi.org/web/wiki/doku.php?id=documentation:oncology:development_schedule https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg
Psychiatry WG Meeting - Thursday at 8am EThttps://zoom.us/j/240721098?pwd=OHhYaWNlelJ6cUlYaG1yYTk1QUlkZz09 https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:psychiatry
OMOP CDM Oncology WG - CDM/Vocabulary Subgroup Meeting - Thursday at 10am EThttps://us04web.zoom.us/j/755053125?pwd=V0dOZVVnY3RMRWgxMVVGTDdVbnA1UT09 https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg
EHR WG - Friday at 10am EThttps://ucdenver.zoom.us/j/4984831362 https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:ehr-wg
You can find a full list of upcoming OHDSI meetings here: https://docs.google.com/document/d/1X0oa9R-V8cwpF1WQZDJOqcXZguPKRiCZ6XrQ2zXMiuQ/edit
ANNOUNCEMENTS
New Teleconferencing Details for OHDSI Community Calls - Our weekly OHDSI community calls, which take place every Tuesday at noon will no longer be hosted via webex. For the time being, these calls will be hosted via Zoom. The details to join are:Zoom Meeting URL: https://columbiacuimc.zoom.us/j/945377669
Women of OHDSI mentorship sessions - The Women of OHDSI will be holding ad hoc mentorship meetings, hosted by experts within a variety of areas. These meetings will have the aim of providing a forum for attendees to ask questions and seek guidance. Each meeting will be structured around a given topic, either focused on a specific technical area (ex. how to write a patient-level prediction protocol) or on general career development (ex. improving soft skills). The meetings may include a short presentation on the topic, but will primarily be designed for attendees to ask questions. To help us organize the meetings, please fill in this googleform and outline areas where you feel you could use more support: https://docs.google.com/forms/d/e/1FAIpQLSdXCGVaNZzhqAoVkWXMQOw0jypD6cMuRo658DgpxrkdC7WrBg/viewform
OHDSI F2F & 2020 US Symposium To do our part in reducing the spread of COVID-19 we have decided not to hold a F2F meeting this summer. However, planning for the 2020 U.S. Symposium, which will take place October 18-21st, is underway, and we will be sharing details when they become available.
COVID-19 Virtual Study-a-thon - To contribute to the COVID-19 response, the OHDSI community hosted a virtual study-a-thon on March 26-29th. For videos from this event, check out this forum post: FINAL GLOBAL UPDATE: #OHDSICOVID19 Study-A-Thon (video link posted) https://www.ohdsi.org/covid-19-updates/
A leader is one who knows the way, goes the way, and shows the way.
COMMUNITY PUBLICATIONS
Deep Phenotyping: Embracing Complexity and Temporality-Towards Scalability, Portability, and Interoperability.
User engagement with web-based genomics education videos and implications for designing scalable patient education materials.
J Wynn, W Wei, X Li, YS So, S Bakken, C Weng and WK Chung,
AMIA ... Annual Symposium proceedings. AMIA Symposium , 2019
Genomic medicine has created an urgent need for scalable genomic education. One promising approach is self-guided learning platforms. Understanding how these platforms are used is critical to guide their effective development and implementation. This study contributes a log-based method to study user engagement with online genomic educational videos among participants in a genomic screening study. We collected baseline demographics, logged participant usage and compared pre- and post-education genomic knowledge. Participants (N=390) who chose website access differed from those who declined access (N=81) and were more likely to be non-Latino, English speaking, younger, and have higher educational attainment. Only 45% who accessed the website viewed at least one video. The average video exposure time was 12 minutes. Longer exposure was not associated with an improvement in the user's genomic knowledge. Our study and future studies of user analytics should be used to guide the development of effective, scalable genomic education methods.
Foundations for Studying Clinical Workflow: Development of a Composite Inter-Observer Reliability Assessment for Workflow Time Studies.
M Lopetegui, PY Yen, P Embi and P Payne,
AMIA ... Annual Symposium proceedings. AMIA Symposium , 2019
The ability to understand and measure the complexity of clinical workflow provides hospital managers and researchers with the necessary knowledge to assess some of the most critical issues in healthcare. Given the protagonist role of workflow time studies on influencing decision makers, major efforts are being conducted to address existing methodological inconsistencies of the technique. Among major concerns, the lack of a standardized methodology to ensure the reliability of human observers stands as a priority. In this paper, we highlight the limitations of the current Inter-Observer Reliability Assessments, and propose a novel composite score to systematically conduct them. The composite score is composed of a) the overall agreement based on Kappa that evaluates the naming agreement on virtually created one-seconds tasks, providing a global assessment of the agreement over time, b) a naming agreement based on Kappa, requiring an observation pairing approach based on time-overlap, c) a duration agreement based on the concordance correlation coefficient, that provides means to evaluate the correlation concerning tasks duration, d) a timing agreement, based on descriptive statistics of the gaps between timestamps of same-task classes, and e) a sequence agreement based on the Needleman-Wunsch sequence alignment algorithm. We hereby provide a first step towards standardized reliability reporting in workflow time studies. This new composite IORA protocol is intended to empower workflow researchers with a standardized and comprehensive method for validating observers' reliability and, in turn, the validity of their data and results.
Leveraging Clinical Expertise as a Feature - not an Outcome - of Predictive Models: Evaluation of an Early Warning System Use Case.
SC Rossetti, C Knaplund, D Albers, A Tariq, K Tang, D Vawdrey, NH Yip, PC Dykes, JG Klann, MJ Kang, J Garcia, LH Fu, K Schnock and K Cato,
AMIA ... Annual Symposium proceedings. AMIA Symposium , 2019
Identifying patients at risk of deterioration in the hospital and intervening more quickly to prevent adverse events is a top patient safety priority. Early warning scores (EWS) identify at risk patients, but there is much opportunity for improvement particularly related to increasing lead time - the time from an alert trigger to adverse event (e.g., cardiac arrest, death). Our team develops healthcare process models of clinical concern (HPM-CC) and in this work has identified documentation signals that are proxies of nurses concern and can be used to predict patient risk earlier than current EWS systems that rely only on physiological data. We compared the performance of a validated EWS - the MEWS - to our novel model (MEWS-CC) comprised of MEWS criteria plus 3 proxy variables of nursing concern. MEWS-CC performed similarly to MEWS, with the added benefit of increased the time from EWS trigger to event by 5-26 hours.
Engaging heart failure patients from a clinical data research network: A survey on willingness to participate in different types of research.
YK Choi, JE López, D Meeker, L Ohno-Machado and KK Kim,
AMIA ... Annual Symposium proceedings. AMIA Symposium , 2019
The willing participation of patients in clinical research is a critical element in national efforts to collect health data for precision medicine and large cohort studies. However, recruiting patients is challenging. Clinical data research networks (CDRN) have primarily been used for observational studies, but may be able to enhance recruitment efforts. We need a better understanding of patient motivation and preferences for research participation and their interest in different types of research activities, particularly among those who are already represented in CDRNs. We surveyed a heart failure patient cohort constructed from EHRs in a CDRN to assess research participation. Results showed that CDRN recruitment is feasible. Respondents were most interested in completing a one-time survey and giving a blood sample one time. They were least interested in a study about weight control that require surgery. We found statistically significant associations between race and research activity interests.
‘Use of antipsychotics in children and adolescents: a picture from the ARITMO population-based European cohort study’.
F Kaguelidou, J Holstiege, T Schink, I Bezemer, E Poluzzi, G Mazzaglia, L Pedersen, M Sturkenboom and G Trifirò,
Epidemiology and psychiatric sciences , Apr 2020 20
Prevalence of the use of antipsychotics (APs) in the paediatric population is globally increasing. The aim of this study was to describe multinational trends and patterns in AP use in children and adolescents in Europe.This was a dynamic retrospective cohort study comprising all children and adolescents (⩽18 years of age). Data were extracted from five population-based electronic healthcare databases in Europe (Denmark, Germany, Italy, the Netherlands and United Kingdom) from 2000 to 2010. Yearly prevalence and incidence of AP use was expressed per 1000 person-years (PYs).Prevalence increased from 1.44 to 3.41/1000 PYs (2008) in Denmark and from 2.07 to 4.35/1000 PYs in the NL (2009), moderately increased from 2.8 to 3.24/1000 in UK (2009) and from 1.53 to 1.74/1000 PYs in Germany (2008) and remained low from 0.61 to 0.34/1000 PYs in Italy (2010). Similarly, incidence rates increased from 0.69 to 1.52/1000 PYs in Denmark and from 0.86 to 1.49/1000 PYs in the NL, stabilised from 2.29 to 2.37/1000 PYs in the UK and from 0.79 to 0.80/1000 PYs in Germany and remained low from 0.32 to 0.2/1000 PYs in Italy. AP use was highest in 15-18 year olds and in boys compared to girls. Yet, the use observed in the 5-9 year olds was found to be comparatively high in the NL. Prescriptions of second generation APs, especially risperidone, were privileged but the first generation APs were still prescribed in the youngest.A steady increase in AP use in children and adolescents was observed essentially in the NL and Denmark. The use in Germany and Italy was lowest among countries. The use of APs under 9 years of age underlines their off-label use and should be carefully monitored as the risk/benefit ratio of these medications remains unclear in young children. AP use was altogether lower in Europe as compared to that reported in North America.
